Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Pathological complete response has been used as a primary endpoint in neoadjuvant trials in early stage triple-negative breast cancer, and the Food and Drug Administration accepted pathological complete response as a surrogate endpoint for long-term survival outcomes in high-risk early stage breast cancer for new drug approval. However, there is insufficient trial-level data to robustly support pathological complete response as a surrogate for long-term survival in triple-negative breast cancer.
Methods: A systematic literature review was performed to identify randomized clinical trials of neoadjuvant systemic therapy for patients with clinical stage I-III triple-negative breast cancer. Data of odds ratios (ORs) for pathological complete response and hazard ratios (HRs) for event-free survival and overall survival were extracted. Disease-free survival was used as an alternative when event-free survival data were unavailable. A linear regression model on a logarithmic scale, coefficient of difference, and 95% confidential interval (CI) were calculated to assess the trial-level association between odds ratio for pathological complete response and hazard ratio for overall survival and event-free survival.
Results: Eight trials with 2342 patients were included. Three trials tested immune checkpoint inhibitors. Coefficient of difference (R2) was 0.2 for hazard ratio of event-free survival (95% CI = 0.17 to 0.22, P = .27), and R2 for hazard ratio of overall survival was 0.19 (95% CI = 0.17 to 0.22, P = .33).
Conclusions: There is no strong evidence to support using pathological complete response as a surrogate marker for event-free survival or overall survival in early stage triple-negative breast cancer at the trial level. Because of the necessity of minimizing drug approval delay with reliable long-term outcome, further studies of surrogate markers in early stage triple-negative breast cancer are warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932712 | PMC |
| http://dx.doi.org/10.1093/jncics/pkaf022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychoacoustic assessment of misophonia.
JASA Express Lett
September 2025
Department of Audiology and Speech-Language Pathology, University of North Texas, Denton, Texas 76201,
Misophonia is a condition characterized by intense negative emotional reactions to trigger sounds and related stimuli. In this study, adult listeners (N = 15) with a self-reported history of misophonia symptoms and a control group without misophonia (N = 15) completed listening judgements of recorded misophonia trigger stimuli using a standard scale. Participants also completed an established questionnaire of misophonia symptoms, the Misophonia Questionnaire (MQ).
View Article and Find Full Text PDFAn observational study on mesangial C4d staining as a prognostic tool in IgA nephropathy.
J Nephrol
September 2025
Institute of Nephrology, Madras Medical College, Chennai, India.
Background: IgA nephropathy is a disease with a highly variable natural history, for which there is an increasing understanding of the role of complement activation in its pathogenesis and progression. We aimed to assess the clinical and prognostic implications of C4d staining in the kidney biopsy of IgA nephropathy patients.
Methods: This was a retrospective observational study wherein the medical records of IgA nephropathy patients were reviewed and baseline characteristics, kidney biopsy findings, treatment response and follow-up data were noted.
Clinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.
J Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.
ASO Visual Abstract: Preoperative Peritoneal MRI: Usefulness to Highlight Potential Hidden Lesions for Complete Cytoreductive Surgery in Colorectal Cancer Patients with Surgical History.
Ann Surg Oncol
September 2025
Department of Radiology, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Timing and contents of early palliative care preferred by patients with advanced cancer in Japan: an Internet-based questionnaire survey.
Support Care Cancer
September 2025
Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Purpose: To clarify the preferred timing and contents of early palliative care and preference for continued care delivery among patients with advanced cancer in Japan.
Methods: We conducted an Internet-based anonymous questionnaire survey on adult patients with advanced cancer. We assessed the patients' wishes for palliative care delivered by a team or at outpatient clinics while asymptomatic, as well as the preferred intervention timing and preference for continuing care lifelong.